P2RY12 and diabetes mellitus: This sub-study aims to evaluate the prognostic significance of DM in patients with AMI treated with pPCI in the era of potent antithrombotics and to investigate whether the most efficient treatment currently available, i.e., primary PCI and potent P2Y12 inhibitors can change the negative impact of DM on the prognoses of patients at the highest risk of major adverse cardiovascular events.